Conmed Q3 adjusted EPS beats estimates
CNMD•Conmed reported Q3 adjusted EPS of $1.04, above the $1.003 analyst estimate, while sales fell 0.7% to $335.56 million, slightly below expectations. It raised 2026 adjusted diluted EPS guidance to $4.54-$4.61 and expects net sales of $1.36 billion to $1.366 billion.
1. Quarterly results
Conmed's Q3 sales were $335.56 million, compared with the $336.23 million analyst estimate, while adjusted EPS was $1.04 versus an estimate of $1.003. Net income was $19.80 million and EPS was $0.66.
2. Updated 2026 outlook
The company raised its 2026 adjusted diluted EPS guidance to $4.54-$4.61. It expects net sales of $1.36 billion to $1.366 billion and organic constant-currency sales growth of 5.0%-5.5%.
3. Sales drivers
Conmed said the sales decline reflected previously announced exits from GI product offerings as part of its portfolio optimization strategy. CEO Patrick J. Beyer attributed organic sales growth to commercial traction in AirSeal, Buffalo Filter and BioBrace. International sales rose 13.1% as reported, with organic constant-currency growth of 13.8%.
